Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients

31 Jul 2019

Abstract excerpt

Circulating biomarkers in blood may provide an interesting alternative to risky tissue biopsies in the diagnosis and follow-up of glioblastoma patients. We have assessed MGMT methylation status in blood and tissue samples from unresected glioblastoma patients who had been included in the randomized GENOM-009 trial. Paired blood and tissue samples were assessed by methylation-specific PCR (MSP) and pyrosequencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31366977
DOI: 10.1038/s41598-019-47642-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patientsPMID 31366977Read ↗

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity Read ↗

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRSemantic proximity Read ↗

Prognostic Role of Methylation Status of theMGMTPromoter Determined Quantitatively by Pyrosequencing in Glioblastoma PatientsSemantic proximity Read ↗

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaSemantic proximity Read ↗

MGMT Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in GlioblastomasSemantic proximity Read ↗

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed GlioblastomaSemantic proximity Read ↗

Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patientsSemantic proximity Read ↗

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patientsSemantic proximity Read ↗

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.Semantic proximity Read ↗

MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma MultiformeSemantic proximity Read ↗

Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastomaSemantic proximity Read ↗

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.